1 Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics

2 in three Kenyan referral hospitals: repeated cross-sectional

3 surveys 2020-21

- 4 R. Lucinde^{1,*}, D. Mugo¹, C. Bottomley², A. Karani¹, E. Gardiner¹, R Aziza³, J. Gitonga¹, H. Karanja¹,
- 5 J. Nyagwange¹, J. Tuju¹, P. Wanjiku¹, E. Nzomo⁴, E. Kamuri⁵, K. Thuranira⁵, S. Agunda⁵, G. Nyutu¹,
- 6 A. Etyang¹, I. M. O. Adetifa^{1,2}, E. Kagucia¹, S. Uyoga¹, M. Otiende¹, E. Otieno¹, L. Ndwiga¹, C. N.
- 7 Agoti¹, R. A. Aman⁶, M. Mwangangi⁶, P. Amoth⁶, K. Kasera⁶, A. Nyaguara¹, W. Ng'ang'a⁷, L. B.
- 8 Ochola⁹, E. Namdala¹⁰, O Gaunya¹⁰, R Okuku¹⁰, E. Barasa^{1,8}, P. Bejon^{1,8}, B. Tsofa¹, L. I. Ochola-
- 9 Oyier¹, G. M. Warimwe^{1,8+}, A. Agweyu¹⁺, J. A. G. Scott^{1,2,8+}, K. E. Gallagher^{1,2+.}
- 10 * Corresponding author: Ruth Lucinde, Epidemiology & Demography Department, KEMRI-
- 11 Wellcome Trust Research Programme CGMR-C, PO Box 230-80108, Kilifi, Kenya. Email:
- 12 <u>RLucinde@kemri-wellcome.org</u>
- 13 Alternate corresponding author: Katherine Gallagher, Department of Infectious Disease
- 14 Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and
- 15 Tropical Medicine, Keppel Street, London, WC1E 7HT, United Kingdom. Email:
- 16 <u>Katherine.gallagher@lshtm.ac.uk</u>
- 17 ⁺Contributed equally
- 18 ¹KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
- ² Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical
 Medicine, Keppel Street, London, UK.
- ³ School of Life Sciences and the Zeeman Institute for Systems Biology & Infectious Disease
- 22 Epidemiology Research (SBIDER), University of Warwick, Coventry, United Kingdom NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 ⁴Kilifi County Hospital, Ministry of Health, Government of Kenya
- 24 ⁵ Kenyatta National Hospital, Ministry of Health, Government of Kenya
- ⁶ Ministry of Health, Government of Kenya, Nairobi, Kenya.
- 26 ⁷ Presidential Policy and Strategy Unit, The Presidency, Government of Kenya, Nairobi, Kenya
- 27 ⁸ Nuffield Department of Medicine, Oxford University, Oxford, UK
- 28 ⁹ Institute of Primate Research, Nairobi, Kenya
- ¹⁰ Busia Country Teaching & Referral Hospital, Busia, Kenya
- 30
- 31 Short title: SARS-CoV-2 seroprevalence at antenatal care clinics in three Kenyan referral
- 32 hospitals
- 33 Abstract word count: 250/300
- 34 Article: 2997/5000
- 35 Keywords: SARS-CoV-2, serology, sero-surveillance, ante-natal care

36 Abstract

37 Introduction

38 The high proportion of SARS-CoV-2 infections that have remained undetected presents a challenge to

39 tracking the progress of the pandemic and estimating the extent of population immunity.

40 Methods

41 We used residual blood samples from women attending antenatal care services at three hospitals in

42 Kenya between August 2020 and October 2021 and a validated IgG ELISA for SARS-Cov-2 spike

43 protein and adjusted the results for assay sensitivity and specificity. We fitted a two-component

44 mixture model as an alternative to the threshold analysis to estimate of the proportion of individuals

45 with past SARS-CoV-2 infection.

46 **Results**

- 47 We estimated seroprevalence in 2,981 women; 706 in Nairobi, 567 in Busia and 1,708 in Kilifi. By
- 48 October 2021, 13% of participants were vaccinated (at least one dose) in Nairobi, 2% in Busia.
- 49 Adjusted seroprevalence rose in all sites; from 50% (95%CI 42-58) in August 2020, to 85% (95%CI
- 50 78-92) in October 2021 in Nairobi; from 31% (95%CI 25-37) in May 2021 to 71% (95%CI 64-77) in
- 51 October 2021 in Busia; and from 1% (95% CI 0-3) in September 2020 to 63% (95% CI 56-69) in

52 October 2021 in Kilifi. Mixture modelling, suggests adjusted cross-sectional prevalence estimates are

underestimates; seroprevalence in October 2021 could be 74% in Busia and 72% in Kilifi.

54 Conclusions

55 There has been substantial, unobserved transmission of SARS-CoV-2 in Nairobi, Busia and Kilifi

- 56 Counties. Due to the length of time since the beginning of the pandemic, repeated cross-sectional
- 57 surveys are now difficult to interpret without the use of models to account for antibody waning.
- 58

- 60
- 61
- 62

63 Introduction

64 Globally, as countries are confronted with new waves of SARS-CoV-2 infections and new variants, 65 WHO recommendations have focused on enhancing population immunity with the available COVID-19 vaccines(1). In Kenya, as with many lower-middle income countries, COVID-19 vaccine supplies 66 have been limited(2). Vaccination started in March 2021 and by 31st October 2021, 3.7 million people 67 68 had received their first dose (13.5% of the adult population), 1.6 million had received their second 69 dose (6% of the adult population), with some geographic heterogeneity. In Nairobi 34% were partially 70 vaccinated, 18% were fully vaccinated, compared to Busia where 8% were partially vaccinated, 3% 71 fully vaccinated, and Kilifi where 5% were partially vaccinated, 2% fully vaccinated(3).

72 As vaccine coverage and vaccine-induced immunity is still considered to be low in Kenya, it remains important to track the potential protection conferred by natural infection. By the 31st October 2021, 73 Kenya had experienced four waves of infections, and reported a total of 253,310 confirmed cases and 74 5281 deaths. However, with just 3.9% of the population over 65 years of age(4), the proportion of 75 infections that have been asymptomatic is likely to be very high(5). Additionally, limited access to 76 77 tests and low uptake of testing makes it likely that a substantial proportion of cases have remained 78 undetected. Measuring the prevalence of antibodies to SARS-CoV-2 is an alternative way to estimate 79 the cumulative incidence of infection. A number of serological assays have been developed and perform well with high sensitivity and specificity(6-9). We have shown that 5.2% of blood donors in 80 81 Kenya had SARS-CoV-2 antibodies in June 2020 and this had risen to 9.1% in September 2020 and 82 48.5% by March 2021(10-12). However, it is unclear whether blood donors are representative of the 83 population.

In the context of a pandemic, sentinel public health surveillance using residual aliquots of routinely collected blood samples has the potential to overcome participation bias. For example, serosurveillance for HIV among women attending antenatal care was used to track the progress of the HIV pandemic and showed prevalence estimates that were similar to population samples from the

88	same areas(13, 14). It remains unclear whether pregnancy alters susceptibility to SARS-CoV-2
89	infection(15); however, a large systematic review has found no difference in risk of becoming
90	symptomatic when comparing pregnant women with confirmed SARS-CoV-2 infection in women of
91	the same age(16, 17).

92 In Kenya, in 2014, 50% of women had had at least one pregnancy or were pregnant by 20 years of age 93 and the coverage of at least one antenatal care visit was 96%(18). Residual blood samples from 94 mothers visiting antenatal care for the first time may therefore represent a relatively unbiased sample 95 of young women, and an alternative sentinel surveillance population to blood donors. Testing an 96 aliquot of blood for antibodies to SARS-CoV-2 is feasible as a venous blood sample (5ml) is already 97 taken to screen mothers for malaria, HIV and syphilis at their first ANC visit. We aimed to determine 98 the prevalence of antibodies against SARS-CoV-2 in mothers attending ANC at three referral 99 hospitals in Kenya.

100 Methods

101 Setting

102 In a collaboration between the Kenyan Ministry of Health (MOH) and KEMRI-Wellcome Trust

103 Research Programme (KWTRP), three referral hospitals were engaged. Kenyatta National Hospital

- 104 (KNH) is the national referral tertiary hospital located in Nairobi, the country's capital city,
- approximately 3km from the central business district. The population of Nairobi city was 4,397,073 in
- 106 2019(4). Busia Country Teaching & Referral Hospital (BCTRH) serves Busia County, an area of
- 107 1628 km², with a population of 893,681 (548/ km²). Kilifi County Hospital (KCH) is the county
- 108 referral hospital in Kilifi Town. Kilifi county covers an area of 12,000 km², with a predominantly
- 109 rural population of 1.4 million $(116/km^2)(4)$.

110 Study population

All women attending ANC for the first time, who provided a routine blood sample at their clinic visit,

- 112 were included in the study. Women who did not provide a sample at their first antenatal care visit, or
- 113 women attending their second or subsequent ANC visit, were excluded.

114 Sample collection and processing

115 In Kenya, a 5ml blood sample is routinely collected at the first ANC visit. After testing for malaria,

syphilis and HIV in the hospital laboratory, the residual volume is usually discarded. In this study, all

- 117 residual samples were set aside and collected daily for SARS-CoV-2 sero-surveillance. Where
- 118 possible, the following data were collected from hospital records and linked to the residual sample

119 identity number: date of sample, age, sub-county of residence, trimester of pregnancy, presence or

absence of COVID19-like symptoms in the last month and COVID-19 vaccination status ascertained

121 via verbal report confirmed via SMS or certificate. No personal identifiers were collected. All samples

122 were tested at the KWTRP laboratories for IgG to SARS-CoV-2 whole spike protein using an

123 adaptation of the Krammer Enzyme Linked Immunosorbent Assay (ELISA)(6). Validation of this

124 assay is described in detail elsewhere(10). Results were expressed as the ratio of test OD to the OD of

125 the plate negative control; samples with OD ratios greater than two were considered positive for

126 SARS-CoV-2 IgG. Sensitivity, estimated in 174 PCR positive Kenyan adults and a panel of 5 sera

127 from the National Institute of Biological Standards in the UK was 92.7% (95% CI 87.9-96.1%);

specificity, estimated in 910 serum samples from Kilifi drawn in 2018 was 99.0% (95% CI 98.1-

129 99.5%)(10).

130 Analysis

We estimated the proportion of samples seropositive for IgG to SARS-CoV-2. Sampling at least 135 women per month from each hospital would provide estimates of seroprevalence in the range 3-25% with a precision of 3-7%. Bayesian modelling was used to adjust seroprevalence estimates for the sensitivity and specificity of the assay. Non-informative priors were used for each parameter

(sensitivity, specificity and proportion true positive) and the models were fitted using the RStan
software package(19) (see supplementary files for code). Sub-county population densities were
extracted from the Kenya National Bureau of Statistics' database(4).

To account for the effects of waning IgG in repeated cross-sectional samples, we fitted a twocomponent mixture model to the log₂ OD ratios in unvaccinated individuals. In this model, we assumed that antibody levels follow a normal distribution in previously uninfected individuals and a skew-normal in previously infected individuals. To fit the model, we fixed the standard deviation of the negative component at the value observed in pre-COVID 19 samples. The remaining parameters were estimated using RStan. Details of the priors used in the estimation have been described elsewhere(20).

145 **Patient and Public Involvement**

146 The study was conducted as anonymous public health surveillance at the request of the Kenyan MOH, 147 in response to the COVID-19 pandemic. The study directly addressed the needs of the MOH by 148 providing some information on the extent of the spread of SARS-CoV-2 pandemic within Kenya. The 149 public were not involved in the conceptualisation or implementation of this study. The need for 150 individual informed consent from the women whose samples were studied was waived, the protocol 151 was approved by the Scientific and Ethics Review Unit (SERU) of the Kenya Medical Research Institute (Protocol SSC 4085), the Kenyatta National Hospital – University of Nairobi Ethics 152 Review Committee (Protocol P327/06/2020) and the Busia & Kilifi County health management 153 154 teams.

155 **Results**

156 Crude and adjusted seroprevalence across time and location

157 In Nairobi, samples were collected in three rounds: round 1, median date 11th August 2020, round 2,

median date 22 February 2021, and round 3, median date 30 September 2021. In these time periods,

159 706 women (93%) provided a sample (Supplementary Figure 1). Women were aged between 17 and 160 45 years (mean 31 years); 275 (40%) attended their first antenatal care visit during their third 161 trimester of pregnancy, although this differed significantly between the rounds: 62% in August 2020, 28% in February 2021 and 35% in September 2021 (p<0.001; Supplementary Table 1). A total of 632 162 163 (90%) reported residence in 16 different sub-counties of Nairobi, 267 (42%) of mothers were resident 164 in Embakasi North, East or West sub-counties, and 110 (17%) were resident in Dagoretti North or South sub-counties. The proportion of participants living in high vs. low population density sub-165 166 counties did not differ by round (supplementary Table 1). Among women who had data on symptoms 167 during the preceding month, 7% reported symptoms in the first two rounds, this significantly differed 168 from the third round where 43% reported symptoms, coinciding with the end of the cold season (June-169 September). Symptoms were not associated with seropositivity, controlling for age (data not shown). 170 In Nairobi, seroprevalence, adjusted for the sensitivity and specificity of the ELISA, was 50% in 171 August 2020, 32% in February 2021 and 85% in September 2021 (Table 1). In October 2021, 12.7% 172 of women were vaccinated with at least one dose of COVID-19 vaccine, seroprevalence among the 173 unvaccinated was 82%.

In Busia, samples were collected in 2 rounds: round 1, median date 3rd May, and round 2, median date 174 175 5th October. In this time period a total of 567 first ANC visits were conducted; 567 (100%) provided a 176 sample (Supplementary Figure 1). Women were aged between 14 and 44 (mean age 27 years). Most women (66%) attended their first ANC in their second trimester, although this differed by round (73%) 177 178 in May and 60% in October (p=0.007; Supplementary table 1). In May, 40% of women reported 179 symptoms in the last month, which differed significantly from October 2021 where 56% reported 180 symptoms. Symptoms were not associated with seropositivity, controlling for age (data not shown). 181 Adjusted seroprevalence in Busia increased from 31% in May 2021 to 71% in October 2021 (Table 182 2). Just 6 (2%) of women were vaccinated in October 2021, and seroprevalence remained 71% among 183 the unvaccinated.

	30 th July – 25 th August 2020 Adjusted				27 th Jan- 11 th March 2021 Adjusted				7 th September-19 th October 2021 Adjusted			
KNH	Seroprevalence		seroprevalence		Seroprevalence		seroprevalence		Seroprevalence		seroprevalence	
Nairobi	n / N	%	%	95% CI	n / N	%	%	95% CI	n / N	%	%	95% CI
All	91 / 196	46.4	49.9	42.1-58.2	80 / 265	30.2	32.1	26.2-38.4	193 / 245	78.8	84.9	78.3-91.5
Age												
17-29 years	39 / 93	41.9	44.9	33.8-56.9	28 / 101	27.7	29.6	20.7-39.2	82 / 101	81.2	87.2	77.9-95.7
30-45 years	44 / 90	48.9	52.5	41.1-63.7	47 / 141	33.3	35.7	27.3-44.3	107 / 139	77.0	83.0	74.0-91.7
Trimester												
First	7 / 17	41.2	44.9	21.2-70.1	27 / 83	32.5	35.0	24.1-46.4	48 / 60	80.0	85.5	73.0-96.1
Second	21 / 53	39.6	42.9	29.8-57.4	34 / 106	32.1	34.5	25.1-44.3	77 / 96	80.2	86.1	76.0-95.5
Third	58 / 114	50.9	54.7	44.6-64.6	18 / 75	24.0	25.8	16.4-37.0	64 / 84	76.2	81.6	71.2-91.7
Any symptoms in l	ast month*											
Yes	7 / 12	58.3	61.2	33.3-86.1	3 / 18	16.7	20.8	5.5-42.2	80 / 106	75.5	81.2	71.3-90.5
No	78 / 172	45.3	48.7	40.2-57.5	77 / 247	31.2	33.3	26.9-40.0	113 / 139	81.3	87.5	79.3-95.1
Population density	of sub-coun	ty of resid	dence									
<20000/km ²	44 / 97	45.4	48.8	38.1-59.4	29 / 104	27.9	29.8	20.6-39.8	86 / 102	84.3	90.6	82.2-97.9
20-81000/km ²	39 / 79	49.4	53.1	41.0-65.7	40 / 124	32.3	34.6	25.9-44.1	85 / 115	73.9	79.5	70.3-88.5
COVID-19 vaccine	e status [†]											
Vaccinated	-	-	-	-	-	-	-	-	30 / 31	96.8	96.1	86.2-99.9
Unvaccinated	-	-	-	-	-	-	-	-	163 / 214	76.2	82.1	75.1-89.2

184 Table 1. Seroprevalence of IgG to SARS-CoV-2 among mothers attending antenatal care in Kenyatta National Hospital (KNH), Nairobi

185

* Women were asked about the full list of COVID-19 symptoms as per the MOH COVID-19 screening form i.e. fever/ chills, general weakness, cough, sore throat, runny

187 nose, shortness of breath, diarrhoea, nausea/ vomiting, headache, irritability/ confusion, pain (muscular/ chest/ abdominal/ joint).

188 *Vaccination status (at least one dose) was not available for the first two rounds of data collection, vaccination began in Kenya in March 2021 and at first targeted specific

groups only, we assume that the vaccine coverage among women attended ANC between 27th Jan-11th March was 0%.

190 Variations in seroprevalence by any of the explanatory variables were not statistically significant in any time period when tested with chi2 test.

191 Table 2. Seroprevalence of IgG to SARS-CoV-2 among mothers attending antenatal care in Busia County Teaching & Referral Hospital (BCTRH),

192 Busia

193

	15	^{5th} April -	21 May 2	021	20 September – 22 October 2021				
BCTRH, Busia	Seroprevalence		Adjusted seroprevalence		Seroprevalence		Adjusted seroprevalence		
	n / N	%	%	95% CI	n / N	%	%	95% CI	
All	78 / 270	28.9	30.6	24.7-37.1	195 / 297	65.7	70.7	64.1-77.4	
Age									
17-29 years	3 / 14	21.4	26.0	6.5-51.4	128 / 203	63.1	67.8	59.8-76.0	
30-45 years	2 / 7	28.6	35.3	7.4-71.3	58 / 84	69.0	74.2	62.7-85.4	
Trimester									
First	18 / 51	35.3	38.2	25.1-52.6	50 / 78	64.1	68.7	56.6-80.1	
Second	50 / 192	26.0	27.7	21.3-34.7	114 / 175	65.1	70.1	61.8-78.4	
Third	7 / 22	31.8	35.3	17.3-55.8	26 / 39	66.7	71.2	54.3-86.4	
Any symptoms in last mor	nth*								
Yes	37 / 109	33.9	36.4	26.6-46.2	107 / 164	65.2	70.1	61.6-78.8	
No	41 / 161	25.5	27.0	19.6-35.1	84 / 129	65.1	70.0	60.4-79.3	
COVID-19 vaccination sta	atus†								
Vaccinated	-	-	-	-	4 / 6	66.7	67.0	29.8-96.1	
Unvaccinated	-	-	-	-	188 / 288	65.3	70.5	63.8-77.3	

¹DOB was only available for 22 women in the first round of data collection

195 * Women were asked about the full list of COVID-19 symptoms as per the MOH COVID-19 screening form i.e. fever/ chills, general weakness, cough, sore throat, runny

196 nose, shortness of breath, diarrhoea, nausea/ vomiting, headache, irritability/ confusion, pain (muscular/ chest/ abdominal/ joint).

197 [†]Vaccination status (at least one dose) was not available for the first two rounds of data collection, vaccination began in Kenya in March 2021 and at first targeted specific

198 groups only, we assume that the vaccine coverage among women attended ANC between 27th Jan-11th March was 0%.

199 Variations in seroprevalence by any of the explanatory variables were not statistically significant in any time period when tested with chi2 test.

- 200 In Kilifi, 1707 samples were collected between the 18th September 2020 and 22nd October 2021,
- 201 collection was continuous apart from during the healthcare worker strike (December 2020 to February
- 202 2021). No data were available on age, trimester, location, symptoms or COVID-19 vaccination status.
- Adjusted seroprevalence increased over the period of sample collection from 1% in September 2020
- to 63% in October 2021 (p=0.0001, Chi sq test for trend; Table 3).

205 Table 3: Seroprevalence of IgG to SARS-CoV-2 among mothers attending antenatal care in

206 Kilifi County Hospital (KCH), over time

KCH, K	Kilifi ¹	Seropre	valence	Adjusted seroprevalence			
		n / N	%	%	95% CI		
Month	Sept-Oct 2020	3 / 265	1.1	0.9	0.0-2.7		
	Nov-Dec 2020	32 / 236	13.6	14.0	9.4-19.5		
	Mar-Apr 2021	55 / 260	21.2	22.2	16.7-28.1		
	May-Jun 2021	104 / 382	27.2	28.9	23.9-34.4		
	Jul-Aug 2021	148 / 260	56.9	61.2	54.4-68.4		
	Sept-Oct 2021	178 / 305	58.4	62.7	56.2-69.1		

¹ No age, trimester or symptom data were available from the ANC records at KCH. Months were combined into
 208 2-month batches due to low numbers
 209

210 Mixture model results

211 When two distinct distributions were fitted to the data—corresponding to antibody levels in

212 previously infected and previously uninfected individuals—there were substantial overlaps in the

213 distributions, especially at low seroprevalences (Figure 1). As seroprevalence estimates increased, the

214 distributions became more distinct. The mixture model produced estimates of cumulative incidence

that were consistently higher than those of the threshold analysis except for the final round in Nairobi,

where the results of both analyses were the same (85%) and the distributions hardly overlapped (85%;

Figure 2). Median OD ratios among the unvaccinated, seropositive individuals increase over time in

all three areas, potentially indicating natural boosting through re-infections (Figure 1, Supplementary

219 Table 2).

220 Figure 1. Mixture distributions fitted to anti-spike IgG antibody data collected in Kilifi (KCH),

- 221 Busia and Nairobi (KNH). The red distribution represents predicted responses in individuals
- 222 previously infected with SARS-CoV-2 and the blue distribution represents predicted responses in
- 223 previously uninfected individuals.

Figure 2. Adjusted and modelled estimates of the cumulative incidence of SARS-CoV-2

infection. Estimates are shown with 95% credible intervals.

226 **Discussion**

227 Surveillance for IgG antibodies to SARS-CoV-2 among mothers attending ANC services in three

228 county referral hospitals in Kenya has revealed evidence of a substantial amount of prior infection by

- 229 October 2021. Seroprevalence is currently highest in Nairobi, then Busia, then Kilifi, correlating with
- the counties' population densities.

231 In Nairobi, in August 2020, just after the peak of the first wave of SARS-CoV-2 infections, mixture 232 modelling, which attempts to account for the wide range of OD ratios among those exposed to the 233 virus better than the simple threshold analysis(20), indicates a cumulative incidence of 75%, just 4 234 months after the start of the pandemic. At the same timepoint, 6,727 PCR-confirmed infections had been registered across the city (<1% of the County's population; Supplementary Figure 2). In March 235 236 2021, a year after the pandemic began, seroprevalence was lower, 32%. This second group of women reported residing in the same sub-counties and were on average the same age (supplementary table 1). 237 238 The high levels of transmission of the virus in these locations early in the pandemic may have meant 239 some of these women had been infected at some point in the last year, but had since seroreverted. 240 Data on the rate of seroreversion differs with the assay used(21) and the severity of the initial infection(22); approximately 9-12% with mild symptoms may sero-revert 4-6 months post-241 infection(23, 24). Additionally, such high seroprevalence earlier in the year may have reduced the 242 243 number susceptible and dampened transmission within the same communities by March 2021. 244 Modelling indicates the first wave could have predominantly affected communities of low-income

245 earners, more likely to use public hospitals, such as KNH, with the later waves affecting a group including higher-income, private healthcare users(25). In October 2021, seroprevalence in a third 246 group of women was 85%, 76% among those unvaccinated. These women were very similar in age, 247 residence location and trimester to the second group. The survey was conducted just after the fourth 248 249 wave of cases in Kenya, natural boosting could have occurred in these communities if residents 250 encountered the virus repeatedly (26). This is supported by the higher median OD ratios among 251 unvaccinated, seropositive individuals in the third round compared to both of the previous rounds. 252 The proportion vaccinated with at least one dose (13%) is lower than the average for Nairobi adults at 253 this time of 34%(3), although nationally only 13.5% of the population were vaccinated with one dose 254 at this time point.

In Busia, seroprevalence in May 2021 was 31% using the threshold analysis, and 51% using the mixture model analysis. The two distributions of OD ratios had a substantial amount of overlap leading to uncertainty in the estimate from mixture modelling at this time point. Threshold seroprevalence increased to 71% in October 2021. By 21st October 2021 only 2% of our study population were vaccinated with at least one dose, lower than the nationally reported coverage of 8% in Busia(3). Western Kenya was affected in the fourth wave of the pandemic in July-September 2021 and the seroprevalence represents a substantial amount of natural infection.

Seroprevalence steadily increased in Kilifi during the sampling timeframe to 63% (using the threshold analysis) or 72% (using the mixture model analysis) in October 2021. The slower increase in seroprevalence in Kilifi compared to Nairobi is consistent with modelling suggesting that the initial wave of the COVID-19 pandemic was concentrated in urban centres, with subsequent spread increasingly affecting rural areas(25); Kilifi County reported a marked increase in the number of infections in December 2020 (Supplementary Figure 2).

A strength of this analysis is the use of a rigorously validated serological assay, using locally relevant control populations and reference panels from the National Institute for Biological Standards and Control (NIBSC) in the UK(27). The threshold used to define seropositivity was chosen to prioritise specificity over sensitivity, i.e. to minimize the number of false positives. The very low crude seroprevalence (0/82; 0%) in the first month of samples from Kilifi adds confirmation that the specificity of this assay is very high.

Although sero-surveillance among pregnant women has been used as a proxy for population-based

275 SARS-CoV-2 surveillance in high income countries(28-34), the representativeness of the sample in

276 Kenya is unknown. A national survey in 2014 indicated 18% of the population utilised public

277 hospitals at their last visit to outpatient services (a further 40% utilized public health centres or

dispensaries). Utilisation of public health services was correlated with lower education levels(35).

279 The seroprevalence estimates from women attending ANC differ from the seroprevalence estimates 280 available from blood donor samples. The Nairobi seroprevalence of 50% in August is substantially higher than the 10% seroprevalence reported among blood donors in the same county in June-August 281 2020(10), however in March 2021, 32% seroprevalence in ANC was lower than the estimated 62% 282 283 seroprevalence in blood donors(12). The majority of expectant mothers attending ANC in KNH 284 consistently came from 5 sub-counties close to the hospital, which are densely populated with lowincome earners(4). Blood transfusion donors are likely to be more heterogenous and widely 285 distributed across Nairobi including areas of lower population density and greater affluence. The 286 estimates from ANC in Kilifi in September 2020 (1%) and April 2021 (22%) were lower than the 287 288 14.1% seroprevalence reported among blood donors from Coastal Counties in September 2020 and 289 the 43% seroprevalence among blood donors in Jan-March 2021(10-12). Blood donations come from 290 across the county including urban centres such as Malindi, whereas women attending ANC in Kilifi 291 represent a less heterogenous semi-urban group. It is clear that viral transmission has been 292 heterogenous in terms of geography and socioeconomic status, seroprevalence estimates from

multiple different sentinel populations provide more reliable indicators of the development of thepandemic than any one estimate alone.

295 The impact of pregnancy on susceptibility to SARS-CoV-2 infection is unclear(15); however, comparisons of infected pregnant women with non-pregnant women of the same age suggests that a 296 297 similar proportion of infections become symptomatic(16). This would suggest a similar proportion of 298 pregnant and non-pregnant women mount a protective antibody response and seroprevalence 299 estimates are generalisable to non-pregnant women of the same age. In a comparison of samples from 300 blood donors and ANC in Australia, the two sample sets estimated seroprevalence within 0.1% of 301 each other, although overall prevalence was very low(36). Additionally, seroprevalence in blood 302 donors in Kenya did not differ by sex(10), suggesting that these results from pregnant women may be 303 generalisable to men between 17-45 years of age, residing in the same areas.

Our analysis is constrained by the nature of the anonymised surveillance data available. Data on age, trimester and location for the women in Kilifi would have allowed more valid comparisons with data from other sources. It is difficult to assess how comparable the different rounds from the same location are, without more data. As discussed, we lack local data on the rate of antibody waning,

308 which is important to estimate cumulative incidence of infection from snapshot seroprevalence

309 estimates(37, 38). This is especially important in populations, like those reported here, where ongoing

transmission may cause 'natural boosting'(37, 39, 40).

311 Conclusions

312 This seroprevalence study of women attending ANC clinics suggests there has been substantial,

313 unobserved transmission of SARS-CoV-2 within communities in Nairobi, Busia and Kilifi Counties.

However, it is becoming difficult to interpret the results of cross-sectional seroprevalence studies due

to the length of the pandemic(41). To attempt to account, to some extent, for antibody waning, we

316 have used mixture modelling, this suggests that 85% of the population using a public hospital in

Nairobi have been previously infected with SARS-COV-2. At least in the short-term, asymptomatic
infection is protective(26) and these seroprevalence estimates should be taken into account when
estimating population level immunity. Increases in antibody concentration over time implies an
increasing level of population protection that may be attributable to reinfections.

321 Acknowledgements

322 We thank the Kenyatta National Hospital, Busia Country Teaching & Referral Hospital and Kilifi

323 County Hospital employees who collected the samples during routine ANC visits and the women

324 themselves for providing samples for routine health screening. We thank Rebeccah Ayako, Evalyne

325 Akinyi and Cedrick Shikoli at the Institute of Primate Research for processing the ANC samples from

326 KNH. We thank F. Krammer for providing the plasmids used to generate the spike protein used in this

327 work. Development of SARS-CoV-2 reagents was partially supported by the NIAID Centres of

328 Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C. The

329 COVID-19 convalescent plasma panel (NIBSC 20/118) and research reagent for SARS-CoV-2 Ab

330 (NIBSC 20/130) were obtained from the NIBSC, UK. We also thank the WHO SOLIDARITY II

network for sharing of protocols and for facilitating the development and distribution of control

reagents. This paper has been published with the permission of the director, Kenya Medical Research

333 Institute.

For the purpose of Open Access, the author has applied a CC-BY public copyright licence to any
author accepted manuscript version arising from this submission.

336 Funding

337 This project was funded by the Wellcome Trust (grants 220991/Z/20/Z and 203077/Z/16/Z), the Bill

and Melinda Gates Foundation (INV-017547), and the Foreign Commonwealth and Development

339 Office (FCDO) through the East Africa Research Fund (EARF/ITT/039) and is part of an integrated

programme of SARS-CoV-2 sero-surveillance in Kenya led by KEMRI Wellcome Trust Research

341 Programme.

- A.A. is funded by a DFID/MRC/NIHR/Wellcome Trust Joint Global Health Trials Award
- 343 (MR/R006083/1), J.A.G.S. is funded by a Wellcome Trust Senior Research Fellowship (214320) and
- 344 the NIHR Health Protection Research Unit in Immunisation, I.M.O.A. is funded by the United
- 345 Kingdom's Medical Research Council and Department For International Development through an
- 346 African Research Leader Fellowship (MR/S005293/1) and by the NIHR-MPRU at UCL (grant
- 347 2268427 LSHTM). G.M.W. is supported by a fellowship from the Oak Foundation. C.N.A. is funded
- 348 by the DELTAS Africa Initiative [DEL-15-003], and the Foreign, Commonwealth and Development
- 349 Office and Wellcome (220985/Z/20/Z). S.U. is funded by DELTAS Africa Initiative [DEL-15-003],
- L.I.O.-O. is funded by a Wellcome Trust Intermediate Fellowship (107568/Z/15/Z). R.A is funded by
- 351 National Institute for Health Research (NIHR) (project reference 17/63/82) using UK aid from the UK
- 352 Government to support global health research.
- 353 The views expressed in this publication are those of the authors and not necessarily those of the
- 354 funding agencies

355 Conflict of Interest

356 All authors: No reported conflicts.

357 Author contributions

- 358 Conceptualisation: A. Agweyu, J. A. G. Scott, G. M. Warimwe, K. E. Gallagher
- 359 Data curation: G. Nyutu
- 360 Formal statistical analysis: K Gallagher, Christian Bottomley
- 361 Funding acquisition: A Agweyu J. A. G. Scott, G. M. Warimwe
- 362 Investigation (Data collection and Lab): R. Lucinde, D. Mugo, A. Karani, E. Gardiner, J. Gitonga, H.
- 363 Karanja, J. Nyagwange, J. Tuju, P. Wanjiku, E. Nzomo, E. Kamuri, K. Thuranira, S. Agunda, L. B.
- 364 Ochola, E. Namdala, O Gaunya, R Okuku

- 365 Methodology: K. Gallagher, C Bottomley
- 366 Project Administration: R Lucinde,
- 367 Supervision: .A Agweyu, J. A. G. Scott, G. M. Warimwe, K. E. Gallagher
- 368 Validation: K Gallagher, G Warimwe
- 369 Vizualisation: K Gallagher, R Aziza, C Bottomley
- 370 Original draft preparation: R Lucinde, K Gallagher
- 371 Review and Editing: R. Lucinde, D. Mugo, C. Bottomley, A. Karani, E. Gardiner, R Aziza, J.
- 372 Gitonga, H. Karanja, J. Nyagwange, J. Tuju, P. Wanjiku, E. Nzomo, E. Kamuri, K. Thuranira, S.
- 373 Agunda, G. Nyutu, A. Etyang, I. M. O. Adetifa, E. Kagucia, S. Uyoga, M. Otiende, E. Otieno, L.
- 374 Ndwiga, C. N. Agoti, R. A. Aman, M. Mwangangi, P. Amoth, K. Kasera, A. Nyaguara , W. Ng'ang'a,
- 375 L. B. Ochola, E. Namdala, O Gaunya, R Okuku, E. Barasa, P. Bejon, B. Tsofa, L. I. Ochola-Oyier, G.
- 376 M. Warimwe, A. Agweyu, J. A. G. Scott, K. E. Gallagher

References 377

- 378 World Health Organization. COVID-19 vaccines 1.
- 379 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines [Accessed 08 380 Dec 2021] 2021 [
- 381 2. World Health Organization. Africa faces 470 million COVID-19 vaccine shortfall in 2021. 16
- 382 September 2021 https://www.afro.who.int/news/africa-faces-470-million-covid-19-vaccine-shortfall-383 2021 2021 [
- Ministry of Health GoK. UPDATES ON COVID-19 VACCINATION EXERCISE 21 October 384 3. 385 2021 https://www.health.go.ke/#1621663315215-d6245403-4901
- 386 4. Kenya National Bureau of Statistics. Population and Housing Census (www.knbs.or.ke). 2019.
- 387 Seedat S, Chemaitelly H, Ayoub H, Makhoul M, Mumtaz GR, Kanaani ZA, et al. SARS-CoV-2 5. infection hospitalization, severity, criticality, and fatality rates. medRxiv. 2020:2020.11.29.20240416. 388
- 389 Amanat F, Nguyen T, Chromikova V, Strohmeier S, Stadlbauer D, Javier A, et al. A serological 6. 390 assay to detect SARS-CoV-2 seroconversion in humans. medRxiv. 2020:2020.03.17.20037713.
- 391 7. Lassaunière R, Frische A, Harboe ZB, Nielsen AC, Fomsgaard A, Krogfelt KA, et al.
- 392 Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv. 2020;2020.04.09.20056325.
- 393 Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN, et al. Test performance 8. 394 evaluation of SARS-CoV-2 serological assays. medRxiv. 2020:2020.04.25.20074856.
- 395 9.
- Caini S, Bellerba F, Corso F, Diaz-Basabe A, Natoli G, Paget J, et al. Meta-analysis of 396 diagnostic performance of serological tests for SARS-CoV-2 antibodies and public health 397 implications. medRxiv. 2020:2020.05.03.20084160.
- 398 Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of 10. 399 anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science (New York, NY). 400 2020:eabe1916.
- 401 Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, et al. Temporal trends 11. 402 of SARS-CoV-2 seroprevalence in transfusion blood donors during the first wave of the COVID-19
- 403 epidemic in Kenya. medRxiv. 2021:2021.02.09.21251404.
- Uyoga S, Adetifa IMO, Otiende M, Yegon C, Agweyu A, Warimwe GM, et al. Prevalence of 404 12.
- 405 SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 406 2021. Jama. 2021;326(14):1436-8.
- 407 Montana LS, Mishra V, Hong R. Comparison of HIV prevalence estimates from antenatal care 13. 408 surveillance and population-based surveys in sub-Saharan Africa. Sexually Transmitted Infections. 409 2008;84(Suppl 1):i78-i84.
- 410 14. Kigadye RM, Klokke A, Nicoll A, Nyamuryekung'e KM, Borgdorff M, Barongo L, et al.
- 411 Sentinel surveillance for HIV-1 among pregnant women in a developing country: 3 years' experience
- and comparison with a population serosurvey. AIDS (London, England). 1993;7(6):849-55. 412
- 413 15. Wastnedge EAN, Reynolds RM, van Boeckel SR, Stock SJ, Denison FC, Maybin JA, et al. Pregnancy and COVID-19. Physiol Rev. 2021;101(1):303-18. 414
- 415 Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, 16.
- 416 risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living
- 417 systematic review and meta-analysis. BMJ. 2020;370:m3320.
- 418 Hill J, Patrick HS, Ananth CV, O'Brien D, Spernal S, Horgan R, et al. Obstetrical outcomes and 17.
- follow-up for patients with asymptomatic COVID-19 at delivery: a multicenter prospective cohort 419 420 study. Am J Obstet Gynecol MFM. 2021;3(6):100454.
- 421 18. Kenya National Bureau of S, Ministry of HK, National ACCK, Kenya Medical Research I,
- 422 National Council for P, Development/Kenya. Kenya Demographic and Health Survey 2014.
- 423 Rockville, MD, USA; 2015.
- 424 Stan Development Team. RStan: the R interface to Stan. R package version 2.21. 2, http://mc-19. 425 stan.org/. 2020 [
- 426 20. Bottomley C, Otiende M, Uyoga S, Gallagher K, Kagucia EW, Etyang AO, et al. Quantifying
- 427 previous SARS-CoV-2 infection through mixture modelling of antibody levels. Nature
- 428 Communications. 2021;12(1):6196.

- 429 21. Eyre DW, Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. Stringent
- thresholds for SARS-CoV-2 IgG assays result in under-detection of cases reporting loss of taste/smell.
 medRxiv. 2020:2020.07.21.20159038.
- 432 22. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid
- 433 Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. New England Journal of
 434 Medicine. 2020;383(11):1085-7.
- 435 23. Duysburgh E, Mortgat L, Barbezange C, Dierick K, Fischer N, Heyndrickx L, et al. Persistence
- 436 of IgG response to SARS-CoV-2. The Lancet Infectious Diseases. 2021;21(2):163-4.
- 437 24. UK Biobank. UK Biobank Serology Study (report at
- 438 <u>https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf</u>
 439). 2021.
- 440 25. Ojal J, Brand SP, Were V, Okiro EA, Kombe IK, Mburu C, et al. Revealing the extent of the

441 COVID-19 pandemic in Kenya based on serological and PCR-test data. medRxiv.

- 442 2020:2020.09.02.20186817.
- 443 26. Boyton RJ, Altmann DM. The immunology of asymptomatic SARS-CoV-2 infection: what are 444 the key questions? Nat Rev Immunol. 2021;21(12):762-8.
- 445 27. Giada Mattiuzzo, Emma M. Bentley, Mark Hassall, Stephanie Routley, Samuel Richardson,
- 446 Valentina Bernasconi, et al. Expert Committee on Biological Standardisation: Establishment of the
- WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody; Geneva 9-10
 December 2020. 2020.
- 28. Crovetto F, Crispi F, Llurba E, Figueras F, Gomez-Roig MD, Gratacos E. Seroprevalence and
- clinical spectrum of SARS-CoV-2 infection in the first versus third trimester of pregnancy. medRxiv.
 2020:2020.06.17.20134098.
- 452 29. Mattern J, Vauloup-Fellous C, Zakaria H, Benachi A, Carrara J, Letourneau A, et al. Post
- lockdown COVID-19 seroprevalence and circulation at the time of delivery, France. PLoS One.
 2020;15(10):e0240782.
- 455 30. Flannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, et al.
- 456 SARS-CoV-2 seroprevalence among parturient women in Philadelphia. Science immunology.
 457 2020;5(49).
- 458 31. Cosma S, Borella F, Carosso A, Sciarrone A, Cusato J, Corcione S, et al. The "scar" of a
 459 pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy. Journal of
 460 medical virology. 2020.
- 461 32. Villalaín C, Herraiz I, Luczkowiak J, Pérez-Rivilla A, Folgueira MD, Mejía I, et al.
- 462 Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and 463 perinatal outcome. PLoS One. 2020;15(11):e0243029.
- 464 33. Lumley SF, Eyre DW, McNaughton AL, Howarth A, Hoosdally S, Hatch SB, et al. SARS-
- 465 CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom,
- 466 14 April to 15 June 2020. Eurosurveillance. 2020;25(42).
- 467 34. Haizler-Cohen L, Davidov A, Blitz MJ, Fruhman G. Severe acute respiratory syndrome
- 468 coronavirus 2 antibodies in pregnant women admitted to labor and delivery units. American journal of469 obstetrics and gynecology. 2020.
- 470 35. Ministry of Health GoK. 2013 KENYA HOUSEHOLD HEALTH EXPENDITURE AND
 471 UTILISATION SURVEY. Nairobi; 2014.
- 472 36. Gidding HF, Machalek DA, Hendry AJ, Quinn HE, Vette K, Beard FH, et al. Seroprevalence of
- 473 SARS-CoV-2-specific antibodies in Sydney, Australia following the first epidemic wave in 2020.
- 474 Med J Aust 2020; <u>https://www.mja.com.au/journal/2020/seroprevalence-sars-cov-2-specific-</u>
- 475 <u>antibodies-sydney-australia-following-first</u> [Preprint, 2 November 2020]. 2020.
- 476 37. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A
 477 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection,
 478 and association with severity. Nature Communications. 2020;11(1):4704.
- 479 38. Buss LF, Prete CA, Jr., Abrahim CMM, Mendrone A, Jr., Salomon T, de Almeida-Neto C, et
- 480 al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated
- 481 epidemic. Science (New York, NY). 2021;371(6526):288-92.

- 482 39. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-
- 483 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature.
 484 2020;584(7821):457-62.
- 485 40. Otieno G, Murunga N, Agoti C, Gallagher K, Awori J, Nokes D. Surveillance of endemic
- 486 human coronaviruses (HCoV-NL63, OC43 and 229E) associated with childhood pneumonia in Kilifi,
- 487 Kenya [version 2; peer review: 2 approved]. Wellcome Open Research. 2020;5(150).
- 488 41. Bottomley C, Otiende M, Uyoga S, Gallagher K, Kagucia EW, Etyang AO, et al. Improving
- 489 SARS-CoV-2 cumulative incidence estimation through mixture modelling of antibody levels.
- 490 medRxiv. 2021:2021.04.09.21254250.




Figure 1




Figure 2